Shares of Man Group PLC rose 6% after UBS upgraded the hedge fund manager to 'buy' and raised its price target, citing a strong rebound in its algorithm-driven AHL funds. These funds have gained 7% since early August, with key strategies surpassing performance fee thresholds, boosting UBS's earnings forecasts by nearly 30% for 2027 and 2028. Man Group is expected to continue using performance fees for share buybacks, supporting the stock. However, UBS warns that fund returns are volatile and difficult to predict, with the next update likely in early October.
Man Group shares rose 6% after UBS upgraded it and raised price targets. For readers following Financials, here is Pluang's market snapshot as of Sep 17, 2026 23:31 WIB: 57 of 74 Financials-sector US stocks rose today. Notable movers include KKR at USD 99.07 (+2.30%), WAL at USD 79.54 (+2.24%), and ARCC at USD 19.77 (+2.09%) with a 99% sell order activity.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
